---
layout: default
title: Palbociclib
parent: 僅模型預測 (L5)
nav_order: 260
evidence_level: L5
indication_count: 4
---

# Palbociclib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the given Evidence Pack, here is the report. Note upfront: `predicted_indications[0]` (highest TxGNN score) is **hyperthyroidism**, which has zero supporting trials/literature and the evidence pack's own rationale states no known mechanistic link — so this is a genuine "Hold" case, not spin.

---

# Palbociclib: From Metastatic Breast Cancer to Hyperthyroidism

## One-Sentence Summary

> Palbociclib is a CDK4/6 inhibitor used in HR+/HER2-negative metastatic breast cancer (per contextual literature in this evidence pack; no formal Norway indication record exists as the drug is not marketed there).
> The TxGNN model predicts it may be effective for **Hyperthyroidism**, with a **99.44%** score,
> but this ranks with **0 clinical trials** and **0 publications** currently supporting the direction — a model-only signal.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not formally recorded (Norway: not marketed, no license text). Contextual literature repeatedly identifies palbociclib as a CDK4/6 inhibitor for HR+/HER2-negative metastatic breast cancer. |
| Predicted New Indication | Hyperthyroidism |
| TxGNN Prediction Score | 99.44% (rank 5957) |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is flagged as a data gap (DG002) in this evidence pack. Based on rationale text embedded in the pack itself, palbociclib is a CDK4/6 inhibitor blocking retinoblastoma protein phosphorylation to arrest the cell cycle at G1/S — a mechanism used therapeutically in HR+/HER2-negative breast cancer.

Critically, the evidence pack's own repurposing rationale for this specific prediction states: *"無可辨識機轉關聯 (no identifiable mechanistic link)... Palbociclib 為 CDK4/6 抑制劑，與甲狀腺激素合成/釋放路徑無已知交互作用"* — i.e., there is no known interaction between CDK4/6 inhibition and thyroid hormone synthesis or release pathways. The high TxGNN score is not corroborated by any biological plausibility argument, clinical trial, or published case evidence.

This is a case where the model's statistical score (99.44%) is high but entirely unsupported — the appropriate interpretation is a candidate for future hypothesis generation, not a repurposing signal ready for review.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Norway Market Information

Palbociclib is **not marketed** in Norway under this evidence pack (`market_status: 未上市`, `total_licenses: 0`). No license records are available to summarize.

---

## Cytotoxicity

Palbociclib is an antineoplastic agent (targeted therapy) per contextual literature in this pack (breast cancer treatment references across multiple citations, e.g., PMID 40504547, 33587021).

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 kinase inhibitor) — not conventional cytotoxic chemotherapy |
| Myelosuppression Risk | High — cited as a common class-effect adverse event in the pack's literature (PMID 37994878: "common adverse events, such as bone marrow suppression") |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC with differential (per bone marrow suppression signal in cited literature); liver and renal function |
| Handling Protection | Not specified in this evidence pack — please refer to institutional hazardous/cytotoxic drug handling guidelines |

---

## Safety Considerations

Please refer to the package insert for safety information. (`key_warnings`, `contraindications`, and DDI query all returned no data in this evidence pack — DG001 flags TFDA label data as a **Blocking** gap preventing S1 safety evaluation.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate has evidence level L5 (model prediction only), zero clinical trials, zero literature, and the pack's own mechanistic rationale explicitly states no known link between CDK4/6 inhibition and thyroid hormone pathways. There is no basis to advance beyond hypothesis stage (S0).

**To proceed, the following is needed:**
- TFDA/regulatory label data (DG001, **Blocking** — required before any S1 safety screening)
- Formal MOA documentation (DG002) to properly assess mechanistic plausibility
- Preclinical or in vitro evidence specifically linking CDK4/6 pathway activity to thyroid hormone regulation, before this indication warrants further evaluation
- *Optional secondary note*: two other TxGNN candidates in this pack had more substantive (though still weak) signal and may be worth independent evaluation — rheumatoid arthritis (L4, case report + preclinical CDK6-synovial hyperplasia mechanism, but conflicting literature on autoimmune induction) and thrombotic disease (L4, but existing evidence points toward CDK4/6i **causing** thromboembolic risk rather than treating it — this candidate should likely be closed rather than pursued).
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

